131 related articles for article (PubMed ID: 38850074)
1. Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder.
Siwach G; Hans R; Takkar A; Ahuja CK; Lamba DS; Lal V; Sharma RR
J Clin Apher; 2024 Jun; 39(3):e22129. PubMed ID: 38850074
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study.
Xu Y; Wang H; Song T; Yin L; Yao Y; Wei Y; Cong H; Sun J; Zhang X; Tian DC
CNS Neurosci Ther; 2024 May; 30(5):e14780. PubMed ID: 38790106
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin as the rescue treatment in NMOSD patients.
Lin J; Xue B; Zhu R; Pan J; Li J; Lin Y; Li X; Xia J
Neurol Sci; 2021 Sep; 42(9):3857-3863. PubMed ID: 33523317
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
[TBL] [Abstract][Full Text] [Related]
7. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
Demuth S; Guillaume M; Bourre B; Ciron J; Zephir H; Sirejacob Y; Kerbrat A; Lebrun-Frenay C; Papeix C; Michel L; Laplaud D; Vukusic S; Maillart E; Cohen M; Audoin B; Marignier R; Collongues N;
J Neuroinflammation; 2022 Mar; 19(1):62. PubMed ID: 35236386
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD).
Li X; Tian DC; Fan M; Xiu Y; Wang X; Li T; Jia D; Xu W; Song T; Shi FD; Zhang X
Mult Scler Relat Disord; 2020 Sep; 44():102325. PubMed ID: 32653803
[TBL] [Abstract][Full Text] [Related]
10. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
[TBL] [Abstract][Full Text] [Related]
11. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
12. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population.
Ong ZM; Schee JP; Viswanathan S
Ther Apher Dial; 2020 Jun; 24(3):312-323. PubMed ID: 31654607
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
15. A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.
Liu J; Zhou R; Gong Y; Ding X; Huang Q; Zhang Y; Feng Y; Wang D; Zhou H; Ma Y; Zhang X; Zhou Y
J Clin Apher; 2022 Jun; 37(3):237-244. PubMed ID: 35104012
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder.
Bonnan M; Debeugny S; Mejdoubi M; Cabre P
Mult Scler; 2020 Apr; 26(4):468-475. PubMed ID: 30843448
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder.
Li Z; Wan L; Liu X; Wang J; Shi X; Zhou H; Xu Q; Wei S; Yang G
Front Immunol; 2022; 13():1113406. PubMed ID: 36685590
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
19. Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder.
Yuan C; Liu X; Cai S; Zhang L; Guo R; Jia Z; Sun Y; Li B
Mult Scler Relat Disord; 2023 Feb; 70():104504. PubMed ID: 36623394
[TBL] [Abstract][Full Text] [Related]
20. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
